| Id: | acc1580 |
| Group: | 2sens |
| Protein: | AMPK |
| Gene Symbol: | PRKAA1 |
| Protein Id: | Q13131 |
| Protein Name: | AAPK1_HUMAN |
| PTM: | phosphorylation |
| Site: | Thr183 |
| Site Sequence: | MMSDGEFLRTSCGSPNYAAPE |
| Disease Category: | Cancer |
| Disease: | Leukemia |
| Disease Subtype: | BCLL |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | acadesine |
| Drug Info: | Acadesine is an antiplatelet aggregation agent used for the treatment of related conditions. |
| Effect: | modulate |
| Effect Info: | Inducing B-CLL cells with acadesine can phosphorylate adenosine monophosphate-activated protein kinase (AMPK) and induce apoptosis. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 12522004 |
| Sentence Index: | 12522004_4-5 |
| Sentence: | "Incubation of B-CLL cells with acadesine induced the phosphorylation of adenosine monophosphate-activated protein kinase (AMPK), indicating that it is activated by acadesine. Nitrobenzylthioinosine (NBTI), a nucleoside transport inhibitor, 5-iodotubercidin, an inhibitor of adenosine kinase, and adenosine completely inhibited acadesine-induced apoptosis and AMPK phosphorylation, demonstrating that incorporation of acadesine into the cell and its subsequent phosphorylation to AICA ribotide (ZMP) are necessary to induce apoptosis." |
Sequence & Structure:
MRRLSSWRKMATAEKQKHDGRVKIGHYILGDTLGVGTFGKVKVGKHELTGHKVAVKILNRQKIRSLDVVGKIRREIQNLKLFRHPHIIKLYQVISTPSDIFMVMEYVSGGELFDYICKNGRLDEKESRRLFQQILSGVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEFLRTSCGSPNYAAPEVISGRLYAGPEVDIWSSGVILYALLCGTLPFDDDHVPTLFKKICDGIFYTPQYLNPSVISLLKHMLQVDPMKRATIKDIREHEWFKQDLPKYLFPEDPSYSSTMIDDEALKEVCEKFECSEEEVLSCLYNRNHQDPLAVAYHLIIDNRRIMNEAKDFYLATSPPDSFLDDHHLTRPHPERVPFLVAETPRARHTLDELNPQKSKHQGVRKAKWHLGIRSQSRPNDIMAEVCRAIKQLDYEWKVVNPYYLRVRRKNPVTSTYSKMSLQLYQVDSRTYLLDFRSIDDEITEAKSGTATPQRSGSVSNYRSCQRSDSDAEAQGKSSEVSLTSSVTSLDSSPVDLTPRPGSHTIEFFEMCANLIKILAQ
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| PRKAA1 | ACADESINE | AMP-activated protein kinase, AMPK activator | 3 | - | cardiovascular disease | ATC |
| PRKAA1 | ACADESINE | AMP-activated protein kinase, AMPK activator | 1 | Completed | chronic lymphocytic leukemia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| PRKAA1-Thr183 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | 0.707 |
| HGSC | -0.707 |
| ccRCC | |
| GBM | |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 183 | D | Colon cancer/carcinoma | Phosphorylation | 25679763 |
| T | 183 | U | Breast cancer | Phosphorylation | 30413706 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
